Pharmacogenetics in Cardiovascular Disease: The Challenge of Moving From Promise to Realization

Abstract Pharmacogenetics in cardiovascular medicine brings the potential for personalized therapeutic strategies that improve efficacy and reduce harm. Studies evaluating the impact of genetic variation on pharmacologic effects have been undertaken for most major cardiovascular drugs, including antithrombotic agents, β‐adrenergic receptor blockers, statins, and angiotensin‐converting enzyme inhibitors. Across these drug classes, many polymorphisms associated with pharmacodynamic, pharmacokinetic, or surrogate outcomes have been identified. However, their impact on clinical outcomes and their ability to improve clinical practice remains unclear. This review will examine the current clinical evidence supporting pharmacogenetic testing in cardiovascular medicine, provide clinical guidance based on the current evidence, and identify further steps needed to determine the utility of pharmacogenetics in cardiovascular care.
Source: Clinical Cardiology - Category: Cardiology Authors: Tags: Review Source Type: research

Related Links:

Authors: Denis Le Seve J, Gourraud Vercel C, Connault J, Artifoni M Abstract Cholesterol crystal embolism is a systemic pathology associated with diffuse atherosclerosis. Pathophysiology corresponds to tissue necro-inflammation secondary to arteriolar occlusion associated with microembolism from atherosclerotic plaques of large diameter arteries. The clinical presentation is heterogeneous and polymorphic. Multiple organs may be the targets, but preferential damage is skin, kidneys and digestive system. It is a serious pathology, underdiagnosed, with a poor prognosis. The risk factors for developing the disease rema...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
TRENTON, N.J. (AP) — U.S. regulators on Friday approved a new type of cholesterol-lowering drug aimed at millions of people who can’t tolerate — or don’t get enough help from — widely used statin pills like Lipitor and Crestor. The Food and Drug Administration approved Esperion Therapeutics Inc.’s Nexletol for people genetically predisposed to have sky-high cholesterol and people who have heart disease and need to further lower their bad cholesterol. The daily pill is to be taken in conjunction with a healthy diet and the highest statin dose patients can handle, the FDA said. High LDL, o...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston Cholesterol Statins Source Type: news
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: New Cholesterol Drug Approved by FDA A new type of cholesterol-lowering drug that works differently than statins has been approved by the U.S....
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
AbstractAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D). Not only is T2D a risk factor for ASCVD, common comorbid conditions, such as dyslipidaemia and hypertension, are also risk factors for ASCVD. Controlling these risk factors with agents with proven cardiovascular benefits (e.g. metformin, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 receptor inhibitors, statins, ACE inhibitors and angiotensin receptor blockers) provides considerable clinical benefits.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
U.S. regulators have approved a new type of cholesterol-lowering drug aimed at millions of people who don't get enough help from widely used statin pills like Lipitor and Crestor
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
The US Food and Drug Administration on Friday approved a drug to treat high cholesterol that works differently than statins, according to Esperion Therapeutics, the company that makes the drug.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
U.S. regulators have approved a new type of cholesterol-lowering drug aimed at millions of people who don't get enough help from widely used statin pills like Lipitor and Crestor
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Esperion Therapeutics Inc said on Friday that U.S. health regulators approved its cholesterol-lowering drug, making it the first non-statin treatment to be cleared for sale in the country in nearly 20 years.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The non-statin drug bempedoic acid was granted approval for adults with familial hypercholesterolemia or established atherosclerotic CVD.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news
Bempedoic acid will provide patients and doctors with another tool to fight heart disease, the number one cause of death worldwide.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Genetics | Heart | Statin Therapy | Study